Free shipping on all orders over $ 500

Bardoxolone

Cat. No. M5238

All AbMole products are for research use only, cannot be used for human consumption.

Bardoxolone Structure
Synonym:

RTA 401; CCDO

Size Price Availability Quantity
1mg USD 36 In stock
5mg USD 80 In stock
10mg USD 110 In stock
50mg USD 175 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Bardoxolone is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor.

In vitro: Bardoxolone exhibits potent inhibitory activities against production of nitric oxide induced by interferon-Ƴ in mouse macrophages with IC50 of 0.1 nM. Bardoxolone Methyl decreases the viability of leukemic HL-60, KG-1, and NB4 cells with IC50 of 0.4, 0.4, and 0.27 μM, respectively. CDDO-Me induces pro-apoptotic Bax protein, inhibits the activation of ERK1/2, and it blocks Bcl-2 phosphorylation, which contributes to the induction of apoptosis. Bardoxolone Methyl potently inhibits both constitutive and inducible NF-kappaB activated by TNF, interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.

In vivo: Bardoxolone (60 mg/kg) reduces the number, size, and severity of lung tumors in vivo. Bardoxolone Methyl significantly reduces the in vivo inflammatory cytokine response following LPS challenge, induces HO-1 protein expression in the spleen, and protects mice against lethal-dose LPS.

Protocol (for reference only)
Cell Experiment
Cell lines HL-60, KG-1, and NB4 cells
Preparation method Leukemic cell lines are cultured at a density of 3.0 × 10^5 cells/mL, and AML mononuclear cells are cultured at 5 × 10^5 cells/mL in the presence or absence of indicated concentrations of CDDO-Me. Appropriate amounts of DMSO (final concentration less than 0.05%) are included as control. For cytotoxicity studies, 1 μM ara-C is added to the cultures. After 24 to 72 hours, viable cells are counted with the trypan blue dye exclusion method using a hematocytometer.
Concentrations ~5 μM
Incubation time 72 hours
Animal Experiment
Animal models Female A/J mice are injected i.p. with vinyl carbamate.
Formulation DMSO
Dosages ~60 mg/kg
Administration Oral gavage
Chemical Information
Molecular Weight 491.66
Formula C31H41NO4
CAS Number 218600-44-3
Solubility (25°C) 21 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] de Zeeuw D, et al. N Engl J Med. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Related IκB/IKK Products
BAY 11-7082

BAY 11-7082 is an inhibitor of cytokine-induced IκB-α phosphorylation (IC50 ~ 10 μM). BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively).

SC-514

SC-514 is a selective and reversible inhibitor of IκB kinase 2 (IKK2) with IC50 of 3-12 μM.

TPCA-1

TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM.

BMS-345541 hydrochloride

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IC50 values of 0.3 μM and 4 μM for IKK-2 and IKK-1 respectively). BMS-345541 binds at an allosteric site of IKK.

Bardoxolone Methyl

Bardoxolone Methyl is an IKK inhibitor with potent pro-apoptotic and anti-inflammatory activities, as well as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway.

  Catalog
Abmole Inhibitor Catalog




Keywords: Bardoxolone, RTA 401; CCDO supplier, IκB/IKK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.